Imunohistochemická analýza vlivu TRC105 na proces jaterni fibrózy

• Thesis title in Czech: Imunohistochemická analýza vlivu TRC105 na proces jaterni fibrózy
• Thesis title in English: Immunohistochemical analysis of TRC105 effects on the liver fibrosis
• Key words: Carotuximab, TRC-105, endoglin, ateroskleróza
• English key words: Carotuximab, TRC-105, endoglin, atherosclerosis
• Academic year of topic announcement: 2020/2021
• Thesis type: diploma thesis
• Thesis language: čeština
• Department: Department of Biological and Medical Sciences (16-16150)
• Supervisor: RNDr. Ivana Němečková, Ph.D.
• Author: hidden - assigned by the advisor
• Date of registration: 30.09.2020
• Date of assignment: 01.03.2022
• Date and time of defence: 07.09.2022 08:00
• Date of electronic submission: 15.08.2022
• Date of proceeded defence: 07.09.2022
• Opponents: Mgr. Zuzana Svobodová, Ph.D.

Guidelines

1. teoretická příprava - načtení odborné literatury k zadanému tématu
2. práce v laboratoři - příprava vzorků a zvládnutí techniky WB
3. sepsání diplomové práce

References

1. Rathouska J, Jezkova K, Nemeckova I, Zemankova L, Varejckova M, Nachtigal P. Endoglin is not expressed with cell adhesion molecules in aorta during atherogenesis in apoe-deficient mice. Histol Histopathol. 2015;30:233-244
2. Nemeckova I, Serwadczak A, Oujo B, Jezkova K, Rathouska J, Fikrova P, Varejckova M, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P. High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta. PLoS One. 2015;10:e0119665
3. Rathouska J, Jezkova K, Nemeckova I, Nachtigal P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 2015;243:383-388
4. Vicen M, Vitverova B, Havelek R, Blazickova K, Machacek M, Rathouska J, Najmanová I, Dolezelova E, Prasnicka A, Sternak M, Bernabeu C, Nachtigal P. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J 2019:fj201802245R. FASEB. 2018;271:15-25
5. López-Novoa JM, Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H959-74. doi: 10.1152/ajpheart.01251.2009.
6. Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis. 2000 Dec;153(2):323-35. doi: 10.1016/s0021-9150(00)00422-6.
7. Lebrin F, Mummery CL. Endoglin-mediated vascular remodeling: mechanisms underlying hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med. 2008 Jan;18(1):25-32. doi: 10.1016/j.tcm.2007.11.003.
8. Fernández-L A, Sanz-Rodriguez F, Blanco FJ, Bernabéu C, Botella LM. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. Clin Med Res. 2006 Mar;4(1):66-78. doi: 10.3121/cmr.4.1.66.
9. Rosen, L.S., Gordon, M.S., Robert, F. et al. Endoglin for Targeted Cancer Treatment. Curr Oncol Rep. 2014;16:365.https://doi.org/10.1007/s11912-013-0365-x
10. Lenato GM, Guanti G. Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des. 2006;12(10):1173-93. doi: 10.2174/138161206776361291.
11. Kumar S, Pan CC, Bloodworth JC, Nixon AB, Theuer C, Hoyt DG, Lee NY. Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling. Oncogene. 2014 Jul 24;33(30):3970-9. doi: 10.1038/onc.2013.386